Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing—A Prospective Feasibility Study
B.M. Berger(Medical University of Graz), Ariane Aigelsreiter(Medical University of Graz), Erika Richtig(Medical University of Graz), Ingrid Wolf(Medical University of Graz), Maximilian C. Koeller(Medical University of Vienna), Emina Talakić(Medical University of Graz), Karl Kashofer(Medical University of Graz), Andrea Thueringer(Medical University of Graz), Hanno Gerritsmann(Novartis (Austria)), Georg Richtig(Medical University of Graz), Barbara M. Rainer(Medical University of Graz), Catharina Koch(Medical University of Graz), Lukas Koch(Medical University of Graz), Doritt Franz(Medical University of Graz), Nadia Dandachi(Medical University of Graz), Peter Michael Rohrer(Medical University of Graz), Martin Pichler(University of Augsburg)
Cited by 4
Related Papers
Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut microbiota-brain communication
|Brain Behavior and Immunity|2016|741
Germline mutations in BAP1 predispose to melanocytic tumors
|Nature Genetics|2011|724
Human platelet lysate can replace fetal bovine serum for clinical‐scale expansion of functional mesenchymal stromal cells
|Transfusion|2007|507
Inferring expressed genes by whole-genome sequencing of plasma DNA
|Nature Genetics|2016|463
Molecular epidemiology and diagnostics of KRAS mutations in human cancer
|Cancer and Metastasis Reviews|2020|334